Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Ontaneda

Showing results (31-40 of 193) with videos related to

Pageof 20
Sort By:
Current Opinion in Neurology|April 19, 2015
Progressive multiple sclerosisDaniel Ontaneda, Robert J Fox
Therapeutic Advances in Drug Safety|August 2, 2014
Benefits versus risks of latest therapies in multiple sclerosis: a perspective reviewDaniel Ontaneda, Daniela Di Capua
Annals of Indian Academy of Neurology|February 26, 2010
Management of acute exacerbations in multiple sclerosisDaniel Ontaneda, Alex D Rae-Grant
Expert Review of Neurotherapeutics|May 2, 2023
The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosisAnnalisa Morgan, Emma Tallantyre, Daniel Ontaneda
Neurology. Clinical Practice|May 10, 2021
Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint InhibitorsJenny Feng, Lindsay Ross, Daniel Ontaneda
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 24, 2022
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yesKunio Nakamura, Yufan Zheng, Daniel Ontaneda
Neurology. Clinical Practice|March 20, 2020
Primary CNS lymphoma initially diagnosed as vasculitisLauren Feldman, Yuebing Li, Daniel Ontaneda
JAMA Neurology|November 10, 2025
2024 Diagnostic Criteria for Multiple Sclerosis-A Unified ApproachKarlo Toljan, Jiwon Oh, Daniel Ontaneda
Multiple Sclerosis and Related Disorders|January 6, 2024
Differentiating multiple sclerosis from non-specific white matter changes using a convolutional neural network image classification modelMoein Amin, Kunio Nakamura, Daniel Ontaneda
Multiple Sclerosis and Related Disorders|September 16, 2014
Risk stratification and mitigation multiple sclerosisDaniel Ontaneda, Samuel Cohn, RobertJ Fox
Pageof 20

Showing results (31-40 of 193) with videos related to

Sort By:
Pageof 20
Current Opinion in Neurology|April 19, 2015
Progressive multiple sclerosisDaniel Ontaneda, Robert J Fox
Therapeutic Advances in Drug Safety|August 2, 2014
Benefits versus risks of latest therapies in multiple sclerosis: a perspective reviewDaniel Ontaneda, Daniela Di Capua
Annals of Indian Academy of Neurology|February 26, 2010
Management of acute exacerbations in multiple sclerosisDaniel Ontaneda, Alex D Rae-Grant
Expert Review of Neurotherapeutics|May 2, 2023
The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosisAnnalisa Morgan, Emma Tallantyre, Daniel Ontaneda
Neurology. Clinical Practice|May 10, 2021
Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint InhibitorsJenny Feng, Lindsay Ross, Daniel Ontaneda
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 24, 2022
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yesKunio Nakamura, Yufan Zheng, Daniel Ontaneda
Neurology. Clinical Practice|March 20, 2020
Primary CNS lymphoma initially diagnosed as vasculitisLauren Feldman, Yuebing Li, Daniel Ontaneda
JAMA Neurology|November 10, 2025
2024 Diagnostic Criteria for Multiple Sclerosis-A Unified ApproachKarlo Toljan, Jiwon Oh, Daniel Ontaneda
Multiple Sclerosis and Related Disorders|January 6, 2024
Differentiating multiple sclerosis from non-specific white matter changes using a convolutional neural network image classification modelMoein Amin, Kunio Nakamura, Daniel Ontaneda
Multiple Sclerosis and Related Disorders|September 16, 2014
Risk stratification and mitigation multiple sclerosisDaniel Ontaneda, Samuel Cohn, RobertJ Fox
Pageof 20